文献速递骨软组织肉瘤与黑色素瘤

Lynch综合征患者发生的肉瘤富含多形性软组织肉瘤且对免疫治疗敏感

Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.
PubMed 文献 · Eur J Cancer · 2024-12-21

SarcLynch是首个全国性回顾性研究,纳入法国23个中心的81例Lynch综合征合并肉瘤患者,发现软组织肉瘤占83%,其中88%含多形性成分,以未分化多形性肉瘤(36%)和多形性横纹肌肉瘤(21%)最常见;8例接受免疫检查点抑制剂的患者中4例(50%)客观缓解。

要点

  • Lynch综合征患者肉瘤以软组织肉瘤为主(83%),且88%含多形性成分。
  • 未分化多形性肉瘤(36%)和多形性横纹肌肉瘤(21%)为最常见亚型。
  • 8例接受免疫检查点抑制剂者中4例(50%)客观缓解,缓解持续6至20个月。

核心结论

  • SarcLynch是描述Lynch综合征患者肉瘤的最大多中心系列,发现多形性肉瘤(尤其未分化多形性肉瘤和多形性横纹肌肉瘤)富集。
  • 该发现强烈支持在这类罕见组织学类型中评估错配修复状态,兼具肿瘤遗传筛查和治疗意义。
  • 考虑到50%的客观缓解率,作者认为这些肿瘤应考虑使用免疫治疗。

研究设计与样本

  • 首个全国性回顾性研究SarcLynch,描述Lynch综合征患者发生的肉瘤的病理和临床特征。
  • 患者来自两个全国性网络,纳入法国23个中心,共81例。

主要发现

  • 81例患者中,软组织肉瘤67例(83%),骨肉瘤14例(17%)。
  • 软组织肉瘤中59例(88%)含多形性成分,未分化多形性肉瘤占36%,多形性横纹肌肉瘤占21%。
  • 肉瘤为32例患者(40%)的首个肿瘤事件;32例(40%)携带MSH2胚系致病性变异。
  • 在接受错配修复缺陷评估的患者中,免疫组化显示75%为错配修复缺陷,45%为微卫星高度不稳定。
  • 8例接受免疫检查点抑制剂,4例(50%)客观缓解,其中3例影像学完全缓解(含1例病理学完全缓解),缓解持续时间6至20个月。

临床怎么用

  • 作者认为,考虑到50%的客观缓解率,这些肿瘤应考虑使用免疫治疗。
  • 作者认为,该发现强烈支持在这类罕见组织学类型中评估错配修复状态,兼具肿瘤遗传筛查和治疗意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcomas do not belong to the Lynch Syndrome (LS)-tumour spectrum. A growing body literature has reported sarcomas in patients with LS. Clinical and tumour characteristics of these patients remain unknown. PATIENTS AND METHODS: We set up the first national retrospective study, SarcLynch, describing the pathological and clinical characteristics of sarcomas developed in patients with LS. Patients were identified from two national networks and included from 23 centres in France. RESULTS: Eighty-one patients participated in the SarcLynch study. Sixty-seven (83 %) tumours were soft-tissue sarcomas (STS) and 14 (17 %) bone sarcomas. Among STS, 59 (88 %) showed a pleomorphic component, with undifferentiated pleomorphic sarcoma (UPS) (36 %) and pleomorphic rhabdomyosarcoma (pRMS) (21 %) being the most represented subtypes. Sarcoma was the first neoplastic event in 32 patients (40 %). Thirty-two patients (40 %) were carriers of MSH2 germline pathogenic variants. Among patients who underwent an assessment of deficient mismatch repair (dMMR) by immunohistochemistry and/or molecular biology status, 75 % were dMMR by immunohistochemistry and 45 % were microsatellite instability high (MSI-H). Eight patients received immune checkpoint inhibitors and 4 (50 %) exhibited an objective response with 3 complete radiological response including 1 patient with pathological complete response. Duration of response ranged from 6 to 20 months. CONCLUSIONS: SarcLynch, the largest multicentric series describing sarcomas developed in patients with LS, revealed an enrichment in patients with pleomorphic sarcomas - especially UPS and pRMS. This finding strongly supports screening for MMR status evaluation in these rare histotypes both for oncogenetic screening and therapeutic interest. Considering an objective response rate of 50 %, access to immunotherapy should be considered in these tumours.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Poumeaud F, Valentin T, Fares N, et al. Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy. Eur J Cancer. 2024. PMID: 39742560. doi:10.1016/j.ejca.2024.115196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。